![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supporting Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supporting Information)
13MB |
| Item Type: | Article |
|---|---|
| Title: | Minor neuropsychological deficits and stage 2 of Alzheimer's disease |
| Creators: |
Stark, Melina  ORCID: https://orcid.org/0009-0005-3812-023X, Wagner, Michael, Kuhn, Elizabeth, Roeske, Sandra, Amthauer, Holger, Bartels, Claudia, Boecker, Henning, Brosseron, Frederic, Buchert, Ralph, Buerger, Katharina, Daamen, Marcel, Drzezga, Alexander, Düzel, Emrah, Ersözlü, Ersin, Essler, Markus, Ewers, Michael, Fliessbach, Klaus, Glanz, Wenzel, Hellmann-Regen, Julian ORCID: https://orcid.org/0000-0003-0411-9204, Incesoy, Enise I., Janowitz, Daniel, Kafali, Konstantinia, Kilimann, Ingo, Krause, Bernd Joachim, Kronmüller, Marie, Laske, Christoph, Maier, Franziska, Maurer, Angelika, Michely, Jochen, Perneczky, Robert, Peters, Oliver ORCID: https://orcid.org/0000-0003-0568-2998, Preis, Lukas ORCID: https://orcid.org/0000-0001-7601-6410, Priller, Josef ORCID: https://orcid.org/0000-0001-7596-0979, Rauchmann, Boris-Stephan, Reimold, Matthias, Rominger, Axel, Schmid, Matthias, Schneider, Anja, Sodenkamp, Sebastian, Spottke, Annika, Spruth, Eike Jakob, Teipel, Stefan, Wiltfang, Jens, Jessen, Frank and Kleineidam, Luca
|
| Abstract: | INTRODUCTION: Subtle symptoms, like subjective cognitive decline (SCD) and minor neuropsychological deficits (MNPD), can improve the risk stratification in preclinical Alzheimer´s disease (AD) but their importance is insufficiently elaborated. METHODS: We pooled data from cognitively normal individuals participating in three longitudinal cohort studies (N = 13,192, 8,359[63.3%] female, mean [SD] age 71.0[8.4]). RESULTS: Compared to participants without SCD and MNPD (SCD-/MNPD-), SCD-/MNPD+, SCD+/MNPD-, and SCD+/MNPD+ participants had an increased risk for mild cognitive impairment (MCI) and dementia, including in amyloid-positive individuals. Focusing on SCD+/MNPD+ participants triples the positive predictive value of amyloid biomarker testing for the 5-year prediction of MCI and reduces the required samples size for trials in preclinical AD to one fourth, compared to considering all cognitively normal participants regardless of subtle symptoms. DISCUSSION: SCD and MNPD offer a powerful approach for risk stratification in preclinical AD, which can improve clinical trial designs, risk counseling, and future case identifications for early treatment. |
| Keywords: | Clinical Staging, Minor Neuropsychological Deficits, Preclinical Alzheimer’s Disease, Stage 2 of Alzheimer’s Disease, Subjective Cognitive Concerns, Subjective Cognitive Decline, Subtle Cognitive Decline, Transitional Cognitive Decline |
| Source: | Alzheimer's & Dementia |
| ISSN: | 1552-5260 |
| Publisher: | Wiley / Alzheimer's Association |
| Volume: | 22 |
| Number: | 5 |
| Page Range: | e71458 |
| Date: | May 2026 |
| Official Publication: | https://doi.org/10.1002/alz.71458 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
